Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 27;30(6):870-880.
doi: 10.5603/CJ.a2022.0047. Online ahead of print.

Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice

Piotr Rola  1   2 , Adrian Włodarczak  3 , Magdalena Łanocha  4 , Mateusz Barycki  5 , Marek Szudrowicz  3 , Jan J Kulczycki  3 , Joanna Jaroszewska-Pozorska  3 , Alicja Gosiewska  6 , Katarzyna Woźnica  6 , Maciej Lesiak  7 , Adrian Doroszko  8
Affiliations

Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice

Piotr Rola et al. Cardiol J. .

Abstract

Background: Acute coronary syndrome (ACS) as a clinical manifestation of coronary artery disease (CAD) remains a significant cause of mortality and morbidity, as reported worldwide annually. The second generation of drug-eluting stents (DES) is a gold standard in percutaneous interventions in ACS patients however, permanent caging of the vessel with metallic DES has some drawbacks. Bioresorbable vascular scaffolds (BRS) were designed as a temporal vessel-supporting technology allowing for anatomical and functional restoration. Nevertheless, following the initial encouraging reports, numerous concerns about the safety of BRS occurred.

Methods: In this study, a 1-year performance of 193 patients with magnesium BRS - Magmaris (Biotronik, Berlin, Germany) was evaluated in comparison to 160 patients with polymer BRS - Absorb (Abbott-Vascular, Chicago, USA) in the non-ST-segment elevation-ACS setting.

Results: The Magmaris, when compared to Absorb showed a significantly lower rate of primary endpoint (death from cardiac causes, myocardial infarction, stent thrombosis) as well as target lesion failure in 30-day and 1 year follow-up. In the Absorb group, a significantly higher rate of stent thrombosis was observed.

Conclusions: Data from the present study suggests encouraging safety a profile and more favorable clinical outcomes of Magnesium BRS in comparison to the polymer Absorb - BRS.

Keywords: Absorb; Magmaris; acute coronary syndrome; bioresorbable scaffolds; magnesium scaffolds; percutaneous coronary intervention.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

Figures

Figure 1
Figure 1
Study population, inclusion and exclusion criteria; ACS — acute coronary syndrome; BRS — bioresorbable scaffolds; PCI — percutaneous coronary intervention; STEMI — ST-segment elevation myocardial infarction; TIMI — Thrombolysis in Myocardial Infraction; QCA — quantitative coronary angiography.
Figure 2
Figure 2
Kaplan-Meyer curves for primary outcome-survival free in both study groups.
See this image and copyright information in PMC

References

    1. Vedanthan R, Seligman B, Fuster V. Global perspective on acute coronary syndrome: a burden on the young and poor. Circ Res. 2014;114(12):1959–1975. doi: 10.1161/CIRCRESAHA.114.302782. - DOI - PMC - PubMed
    1. Dudek D, Siudak Z, Grygier M, et al. Interventional cardiology in Poland in 2019. Summary report of the Association of Cardiovascular Interventions of the Polish Cardiac Society (AISN PTK) and Jagiellonian University Medical College. Advances Interventional Cardiology. 2020;16(2):123–126. doi: 10.5114/aic.2020.96054. - DOI - PMC - PubMed
    1. Torii S, Jinnouchi H, Sakamoto A, et al. Drug-eluting coronary stents: insights from preclinical and pathology studies. Nat Rev Cardiol. 2020;17(1):37–51. doi: 10.1038/s41569-019-0234-x. - DOI - PubMed
    1. Ochijewicz D, Tomaniak M, Opolski G, et al. Inflammation as a determinant of healing response after coronary stent implantation. Int J Cardiovasc Imaging. 2021;37(3):791–801. doi: 10.1007/s10554-020-02073-3. - DOI - PMC - PubMed
    1. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58(15):1578–1588. doi: 10.1016/j.jacc.2011.05.050. - DOI - PubMed